PREMENSTRUAL SYNDROME TREATMENT IN ADOLESCENTS AND REPRODUCTIVE-AGE WOMEN

Objective. To evaluate the therapeutic efficacy of a combined monophasic contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone in adolescent and reproductive-age patients with premenstrual syndrome during 12 cycles. Subjects and methods. A non-randomized multicenter open-label clinical trial was conducted under active control. One hundred and twenty-six patients aged 15—45 years (mean age 29.5±6.12 years) receiving a continuous-use drug for 12 months for contraceptive and therapeutic purposes. The findings were processed by descriptive statistics methods. Results. The long-term effect of drospirenone well documented the amelioration of symptoms observing at a standard oral contraceptive-free interval. The results of treatment showed that this agent alleviated the signs of metabolic, endocrine, and autonomic vascular disorders and effectively reduced psychoemotional manifestations. The highest therapeutic efficacy of the continuous-use contraceptive was observed following 12-month therapy for all clinical forms. Its positive contraceptive, cosmetic effects and stable weight maintenance were also noted. Conclusion. The agent may be successfully used to optimize the treatment of premenstrual syndrome.

premenstrual syndrome, monophasic combined oral contraceptives, drospirenone